

#7/4B



SEQUENCE LISTING

Sub C1

<110> WALDMANN, Herman
GILLILAND, LISA K
TONE, MASAHIDE
FREWIN, MARK R
WALSH, LOUISE

<120> ANTIBODY VARIANTS

<130> PP/NT/2794 .US

<140> 09/125,460

<141> 1998-08-19

<150> PCT/GB97/00472

<151> 1997-02-20

<150> GB 9603507.6

<151> 1996-02-20

<160> 7

<170> PatentIn Ver. 2.1

<210> 1

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Peptide

<400> 1

Phe Ile Arg Asp Lys Ala Lys Gly Tyr Thr Thr Glu Tyr Asn Pro Ser

1

5

10

15

Val Leu Gly

<210> 2

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Peptide

<400> 2

Phe Ile Arg Asp Asp Ala Lys Gly Tyr Thr Thr Glu Tyr Asn Pro Ser

1

5

10

15

Val Leu Gly

<210> 3

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Peptide

<400> 3

Phe Ile Arg Lys Lys Ala Lys Gly Tyr Thr Thr Glu Tyr Asn Pro Ser

1

5

10

15

Val Leu Gly

<210> 4

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Peptide

<400> 4

Phe Ile Arg Asp Lys Ala Asp Gly Tyr Thr Thr Glu Tyr Asn Pro Ser

1

5

10

15

Val Leu Gly

<210> 5

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Peptide

<400> 5

Phe Ile Arg Asp Asp Ala Asp Gly Tyr Thr Thr Glu Tyr Asn Pro Ser

1

5

10

15

Val Leu Gly

<210> 6

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Peptide

<400> 6

Phe Ile Arg Lys Asp Ala Asp Gly Tyr Thr Thr Glu Tyr Asn Pro Ser

1

5

10

15

Val Leu Gly

<210> 7

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Peptide

<400> 7

Phe Ile Ala Lys Asp Ala Lys Gly Tyr Thr Thr Glu Tyr Asn Pro Ser

1

5

10

15

Val Leu Gly